PCRX Pacira Biosciences Inc.

Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL

Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL

TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 AM to approximately 12:00 PM ET. Key Opinion Leaders and members of the Pacira executive team will provide updates on the Company’s commercial products and pipeline opportunities. The event is taking place at The Pacira Innovation and Training Center at Tampa (the PITT). In-person attendance requires advance registration and is subject to space limitations.  

An agenda as well as a live webcast of the event will be accessible through . An archived replay of the webcast will also become available through the same link following the conclusion of the event.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .



Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
 
EN
08/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Incre...

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quart...

 PRESS RELEASE

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 S...

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee -- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has concluded patient...

 PRESS RELEASE

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera ...

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control -- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control --  -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an exclusive wor...

 PRESS RELEASE

Pacira to Report Third Quarter 2025 Financial Results on Thursday Nove...

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and an...

 PRESS RELEASE

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sust...

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee -- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced updated three-year results and a ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch